Stock Price
129.58
Daily Change
-2.48 -1.88%
Monthly
-6.47%
Yearly
26.42%
Q2 Forecast
126.98

Gilead Sciences reported $162.52B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 364.22B 20.46B May/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
ALKERMES USD 5.66B 217M May/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amgen USD 189.89B 13.64B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.18B 683M May/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Gilead Sciences USD 167.39B 5.6B May/2026
GlaxoSmithKline GBP 83.8B 9.44B Mar/2026
Incyte USD 21.73B 3B May/2026
J&J USD 579.15B 78.91B Mar/2026
Merck USD 297.1B 35.84B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Neurocrine Biosciences USD 15.15B 1.9B May/2026
Novartis USD 232.75B 75B May/2026
Pfizer USD 147.4B 6.42B May/2026
PTC Therapeutics USD 4.94B 698M May/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Sanofi EUR 100.27B 605.48M Mar/2026
Sarepta Therapeutics USD 2.16B 123M May/2026
United Therapeutics USD 28.08B 2.9B May/2026
Vertex Pharmaceuticals USD 113.58B 1000K May/2026